White paper: Are we prepared for the influx of CAR-Ts?

Chimeric antigen receptor (CAR)-T continues to take centre stage as a paradigm shift in the treatment of cancer. The phrase ‘paradigm shift’ gets thrown about a lot in the discussion of new developments in medicine, but when it comes to CAR-T therapies we believe that it is really justified in this case, due to their potential to be transformative – as evidenced by Gilead’s December 2021 announcement that Yescarta shows durable long-term survival in patients with refractory large B-cell lymphoma.

However, will market access and hospital processes also need to transform to accommodate these therapies? In this
issue of Free Thinking, we take a look.